Acute Hereditary Angioedema Products: Berinert, Kalbitor, and Ruconest
Customize your policy alerts
Sign up for marylandphysicianscarempc Policy RX.PA.001.MPC alerts
Get alerted when Policy RX.PA.001.MPC changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, and renewal requirements for Berinert, Kalbitor, and Ruconest for treatment of acute hereditary angioedema (HAE) attacks for Maryland Physicians Care members and providers.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.